Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700
Debt
Debt-to-Equity Ratio0.01
Current Ratio3.86
Quick Ratio3.84
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.54 billion
Price / Sales10.21
Cash Flow$0.8880 per share
Price / Cash83.37
Book Value$7.73 per share
Price / Book9.58
Profitability
EPS (Most Recent Fiscal Year)$0.64
Net Income$-313,140,000.00
Net Margins-10.90%
Return on Equity-0.74%
Return on Assets-0.52%
Miscellaneous
Employees1,208
Outstanding Shares211,970,000
Incyte (NASDAQ:INCY) Frequently Asked Questions
What is Incyte's stock symbol?
Incyte trades on the NASDAQ under the ticker symbol "INCY."
How were Incyte's earnings last quarter?
Incyte Co. (NASDAQ:INCY) released its quarterly earnings data on Tuesday, May, 1st. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.08. The biopharmaceutical company earned $382.28 million during the quarter, compared to analysts' expectations of $384.03 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 0.74%. The firm's quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.14 EPS. View Incyte's Earnings History.
When is Incyte's next earnings date?
What price target have analysts set for INCY?
22 equities research analysts have issued 12-month price targets for Incyte's stock. Their forecasts range from $65.00 to $174.00. On average, they anticipate Incyte's stock price to reach $115.3055 in the next twelve months. View Analyst Ratings for Incyte.
Who are some of Incyte's key competitors?
Some companies that are related to Incyte include Iqvia (IQV), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).
Who are Incyte's key executives?
Incyte's management team includes the folowing people:
- Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 58)
- Mr. David W. Gryska M.B.A., MBA, Exec. VP & CFO (Age 63)
- Dr. Reid M. Huber, Exec. VP & Chief Scientific Officer (Age 46)
- Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 55)
- Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 51)
Has Incyte been receiving favorable news coverage?
News stories about INCY stock have trended somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Incyte earned a coverage optimism score of 0.09 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.67 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Incyte's major shareholders?
Incyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include BAKER BROS. ADVISORS LP (16.30%), BlackRock Inc. (6.73%), Manning & Napier Group LLC (0.89%), Franklin Resources Inc. (0.72%), Carmignac Gestion (0.51%) and Legal & General Group Plc (0.37%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein and Vijay K Iyengar. View Institutional Ownership Trends for Incyte.
Which major investors are selling Incyte stock?
INCY stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Frontier Capital Management Co. LLC, Federated Investors Inc. PA, American Century Companies Inc., Old Mutual Global Investors UK Ltd., Legal & General Group Plc, Millennium Management LLC and New York State Common Retirement Fund. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Herve Hoppenot, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein and Vijay K Iyengar. View Insider Buying and Selling for Incyte.
Which major investors are buying Incyte stock?
INCY stock was purchased by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Nippon Life Global Investors Americas Inc., Neuberger Berman Group LLC, Carmignac Gestion, Element Capital Management LLC, State of Tennessee Treasury Department, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp and Employees Retirement System of Texas. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.
How do I buy shares of Incyte?
Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Incyte's stock price today?
One share of INCY stock can currently be purchased for approximately $74.03.
How big of a company is Incyte?
Incyte has a market capitalization of $15.37 billion and generates $1.54 billion in revenue each year. The biopharmaceutical company earns $-313,140,000.00 in net income (profit) each year or $0.64 on an earnings per share basis. Incyte employs 1,208 workers across the globe.
How can I contact Incyte?
Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]
MarketBeat Community Rating for Incyte (INCY)
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
